Xeloda

Withhold, adjust dose, or permanently discontinue based on adverse reactions (see full labeling). Not recommended for those known to have certain homozygous or compound heterozygous DPYD variants resulting in complete dihydropyrimidine dehydrogenase deficiency; may have increased risk for serious adverse reactions. Consider testing for genetic variants of DPYD prior to initiation. Cardiotoxicity (esp. with a prior history of coronary artery disease). Monitor hydration status and renal function at baseline and as clinically indicated. Optimize hydration prior to initiation. Monitor for new or worsening serious skin reactions (eg, SJS, TEN). Permanently discontinue if severe cutaneous adverse reactions occur. Myelosuppression. Monitor CBCs at baseline and before each cycle. Do not administer if baseline neutrophils <1.5×10⁹/L or platelets <100×10⁹/L. Hyperbilirubinemia. Advise patients not to cut or crush tabs; should be handled by trained professionals. Hepatic or renal impairment (CrCl <30mL/min): monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Withhold, adjust dose, or permanently discontinue based on adverse reactions (see full labeling). Not recommended for those known to have certain homozygous or compound heterozygous DPYD variants resulting in complete dihydropyrimidine dehydrogenase deficiency; may have increased risk for serious adverse reactions. Consider testing for genetic variants of DPYD prior to initiation. Cardiotoxicity (esp. with a prior history of coronary artery disease). Monitor hydration status and renal function at baseline and as clinically indicated. Optimize hydration prior to initiation. Monitor for new or worsening serious skin reactions (eg, SJS, TEN). Permanently discontinue if severe cutaneous adverse reactions occur. Myelosuppression. Monitor CBCs at baseline and before each cycle. Do not administer if baseline neutrophils <1.5×10⁹/L or platelets <100×10⁹/L. Hyperbilirubinemia. Advise patients not to cut or crush tabs; should be handled by trained professionals. Hepatic or renal impairment (CrCl <30mL/min): monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Withhold, adjust dose, or permanently discontinue based on adverse reactions (see full labeling). Not recommended for those known to have certain homozygous or compound heterozygous DPYD variants resulting in complete dihydropyrimidine dehydrogenase deficiency; may have increased risk for serious adverse reactions. Consider testing for genetic variants of DPYD prior to initiation. Cardiotoxicity (esp. with a prior history of coronary artery disease). Monitor hydration status and renal function at baseline and as clinically indicated. Optimize hydration prior to initiation. Monitor for new or worsening serious skin reactions (eg, SJS, TEN). Permanently discontinue if severe cutaneous adverse reactions occur. Myelosuppression. Monitor CBCs at baseline and before each cycle. Do not administer if baseline neutrophils <1.5×10⁹/L or platelets <100×10⁹/L. Hyperbilirubinemia. Advise patients not to cut or crush tabs; should be handled by trained professionals. Hepatic or renal impairment (CrCl <30mL/min): monitor. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).